Anti Cd 20 Ocrevus denied as not medically necessary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for anti cd20 ocrevus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Ocrevus for Medical Necessity — and Your Path to Reversal

A medical-necessity denial means UnitedHealthcare's reviewer determined that the clinical evidence submitted with your prior-authorization request did not satisfy the criteria in UHC's Medical Policy for ocrelizumab. This is the most common denial type for high-cost MS therapies, and it is the denial type most directly addressed by a strong appeal.

UHC's medical-necessity criteria for ocrelizumab typically address: confirmed MS diagnosis and subtype, clinical disease activity or functional severity, and (for relapsing forms) prior treatment history. A denial usually means one or more of those criteria was not adequately documented — not necessarily that you fail to meet them.

## Your Federal Appeal Rights

• Internal appeal: Under ERISA §503 (employer plans) or applicable state law (individual market), you are entitled to a full-and-fair review of the clinical determination. File within the deadline on your denial notice — commonly 180 days.
• External review: Under ACA §2719, any adverse benefit determination based on medical necessity is subject to independent external review. File within approximately four months of the final internal denial. Expedited external review (72-hour decision) is available if the standard timeline would seriously jeopardize your health or treatment course.
• Right to the reviewer's rationale: UHC must provide the clinical criteria used and, on request, the credentials of the reviewing clinician. You may request this before or during the appeal.

## Concrete Steps and Timeline

1. Request the full denial letter plus the UHC Medical Policy cited in the denial. The policy document lists every criterion that must be met. 2. Read each criterion carefully. Identify which specific criterion UHC's reviewer found unmet or inadequately documented. 3. Assemble a targeted documentation package (see below) that directly addresses each unmet criterion. 4. File the internal appeal with a cover letter that maps each policy criterion to the specific chart evidence you are submitting. 5. If denied at internal level, request external review before the four-month window closes. External reviewers apply evidence-based clinical standards and are not bound by UHC's internal policy.

## Documentation to Gather

• Diagnosis confirmation: Neurologist chart notes, MRI reports, and any CSF or evoked-potential studies establishing MS diagnosis and subtype with precision. Confirm that the ICD-10 code on the claim matches the documented subtype.
• Clinical severity and disease activity: Most recent EDSS or equivalent functional assessment, relapse frequency and severity records, MRI reports showing lesion activity or progression, and any records of functional decline.
• Prior treatment history: A complete, dated list of prior disease-modifying therapies, with outcomes — including why each was stopped (inadequate efficacy, adverse event, intolerance, or contraindication). This is critical for relapsing forms of MS.
• Prescriber medical-necessity letter: A detailed letter from your neurologist addressing each UHC policy criterion explicitly, explaining why ocrelizumab is medically necessary for your specific clinical situation, and referencing applicable AAN or ECTRIMS guideline support.
• Applicable guideline references: Your neurologist's letter should note which professional society guidelines (AAN, ECTRIMS, National MS Society) support the treatment decision.

## Criteria-Mapping Structure

This is the core of a medical-necessity appeal. Obtain UHC's Medical Policy for ocrelizumab. For each listed criterion, document your answer:

| UHC Policy Criterion | Chart Evidence | |---|---| | Confirmed MS diagnosis + subtype | [Neurologist note date, MRI date, ICD-10 code] | | Disease activity or severity threshold | [EDSS score, MRI lesion count/activity, relapse record] | | Prior DMT history (relapsing forms) | [Therapy, dates, outcome — per policy requirements] | | Prescriber specialty and attestation | [Neurologist name, specialty, letter date] |

The more precisely your appeal answers each criterion with a specific chart fact, the harder it is for UHC to sustain a denial at internal appeal or external review.